

1. Sales January to March 2007 and 2006

January – March	2007	2006	% change	
	CHF m	CHF m	In CHF	In local currencies
Pharmaceuticals Division	9,142	7,739	+18	+20
Roche Pharmaceuticals	5,702	4,821	+18	+18
Genentech	2,547	2,056	+24	+30
Chugai	893	862	+4	+11
Diagnostics Division	2,216	2,091	+6	+6
Roche Group	11,358	9,830	+16	+17

2. Quarterly local sales growth by Division in 2006 and 2007

	Q2 2006 vs. Q2 2005	Q3 2006 vs. Q3 2005	Q4 2006 vs. Q4 2005	Q1 2007 vs. Q1 2006
Pharmaceuticals Division	+19	+25	+22	+20
Roche Pharmaceuticals	+15	+25	+20	+18
Genentech	+39	+33	+37	+30
Chugai	+1	+2	+2	+11
Diagnostics Division	+5	+6	+5	+6
Roche Group	+16	+20	+18	+17

3. Quarterly sales by Division in 2006 and 2007

CHF millions	Q1 2006	Q2 2006	Q3 2006	Q4 2006	Q1 2007
Pharmaceuticals Division	7,739	7,838	8,335	9,382	9,142
Roche Pharmaceuticals	4,821	4,849	5,251	5,745	5,702
Genentech	2,056	2,167	2,299	2,603	2,547
Chugai	862	822	785	1,034	893
Diagnostics Division	2,091	2,181	2,143	2,332	2,216
Roche Group	9,830	10,019	10,478	11,714	11,358

4. Top 20 Pharmaceuticals Division product sales¹ and local growth² in YTD March 2007: US, Japan and Europe/Rest of World

	Total		US		Japan		Europe/RoW	
	CHF m	%	CHF m	%	CHF m	%	CHF m	%
MabThera/Rituxan	1,309	17%	682	13%	38	1%	589	23%
Herceptin	1,168	36%	383	7%	36	23%	749	61%
Avastin	923	41%	657	34%	-	-	266	63%
Tamiflu	865	47%	147	-8%	246	55%	472	76%
NeoRecormon/Epogin	522	-3%	-	-	124	-17%	398	3%
CellCept	476	7%	217	3%	7	21%	252	10%
Pegasys	400	15%	104	6%	10	-38%	286	23%
Xeloda	267	14%	89	2%	6	3%	172	22%
Lucentis	263	-	263	-	-	-	-	-
Tarceva	243	44%	125	9%	-	-	118	125%
Bonviva/Boniva	170	132%	120	83%	-	-	50	658%
Xenical	163	-10%	24	-24%	-	-	139	-7
Xolair	136	16%	136	16%	-	-	-	-
Valcyte/Cymevene	124	15%	56	8%	-	-	68	21%
Nutropin	117	5%	114	5%	-	-	3	0%
Pulmozyme	111	4%	65	6%	-	-	46	1%
Kytril	105	-16%	39	-28%	29	7%	37	-15%
Rocephin	100	-7%	6	-34%	12	4%	82	-5%
Neutrogen	96	11%	-	-	96	11%	-	-
Activase/TNKase	96	15%	88	18%	-	-	8	-6%

¹ Roche Pharmaceuticals, Genentech and Chugai combined ² versus YTD March 2006

5. Top 20 Pharmaceuticals Division quarterly local product sales growth¹ in 2006 and 2007

	Q2 2006 vs. Q2 2005	Q3 2006 vs. Q3 2005	Q4 2006 vs. Q4 2005	Q1 2007 vs. Q1 2006
MabThera/Rituxan	16%	13%	17%	17%
Herceptin	103%	72%	58%	36%
Avastin	102%	55%	49%	41%
Tamiflu	133%	141%	43%	47%
NeoRecormon/Epogin	0%	-4%	-1%	-3%
CellCept	-1%	7%	7%	7%
Pegasys	3%	1%	6%	15%
Xeloda	21%	13%	16%	14%
Lucentis	-	-	-	-
Tarceva	119%	110%	71%	44%
Bonviva/Boniva	323%	929%	251%	132%
Xenical	8%	-1%	6%	-10%
Xolair	30%	34%	23%	16%
Valcyte/Cymevene	12%	26%	30%	15%
Nutropin	1%	5%	8%	5%
Pulmozyme	4%	8%	11%	4%
Kytril	-4%	0%	-10%	-16%
Rocephin	-63%	-35%	-32%	-7%
Neutrogen	12%	1%	7%	11%
Activase/TNKase	21%	9%	14%	15%

¹ Roche Pharmaceuticals, Genentech and Chugai combined

6. Pharmaceuticals Division quarterly local product sales growth¹ US in 2006 and 2007

	Q2 2006 vs. Q2 2005	Q3 2006 vs. Q3 2005	Q4 2006 vs. Q4 2005	Q1 2007 vs. Q1 2006
MabThera/Rituxan	16%	9%	15%	13%
Herceptin	110%	40%	29%	7%
Avastin	72%	34%	36%	34%
Tamiflu	143%	229%	33%	-8%
NeoRecormon/Epogin	-	-	-	-
CellCept	6%	9%	13%	3%
Pegasys	-10%	-11%	-6%	6%
Xeloda	24%	11%	16%	2%
Lucentis	-	-	-	-
Tarceva	46%	37%	27%	9%
Bonviva/Boniva	262%	818%	205%	83%
Xenical	15%	6%	11%	-24%
Xolair	30%	34%	23%	16%
Valcyte/Cymevene	20%	32%	38%	8%
Nutropin	1%	5%	8%	5%
Pulmozyme	0%	7%	8%	6%
Kytril	-20%	5%	-26%	-28%
Rocephin	-96%	-89%	-94%	-34%
Neutrogen	-	-	-	-
Activase/TNKase	19%	9%	11%	18%

¹ Roche Pharmaceuticals and Genentech combined

7. Pharmaceuticals Division quarterly local product sales growth Japan¹ in 2006 and 2007

	Q2 2006 vs. Q2 2005	Q3 2006 vs. Q3 2005	Q4 2006 vs. Q4 2005	Q1 2007 vs. Q1 2006
MabThera/Rituxan	-1%	3%	1%	1%
Herceptin	30%	33%	26%	23%
Avastin	-	-	-	-
Tamiflu	367%	6485%	36%	55%
NeoRecormon/Epogin	-9%	-22%	-12%	-17%
CellCept	20%	19%	14%	21%
Pegasys	-24%	-34%	-37%	-38%
Xeloda	-5%	-9%	-9%	3%
Lucentis	-	-	-	-
Tarceva	-	-	-	-
Bonviva/Boniva	-	-	-	-
Xenical	-	-	-	-
Xolair	-	-	-	-
Valcyte/Cymevene	-	-	-	-
Nutropin	-	-	-	-
Pulmozyme	-	-	-	-
Kytril	9%	4%	5%	7%
Rocephin	8%	2%	4%	4%
Neutrogen	12%	1%	7%	11%
Activase/TNKase	-	-	-	-

¹ Chugai

8. Pharmaceuticals Division quarterly local product sales growth Europe/Rest of World¹ in 2006 and 2007

	Q2 2006 vs. Q2 2005	Q3 2006 vs. Q3 2005	Q4 2006 vs. Q4 2005	Q1 2007 vs. Q1 2006
MabThera/Rituxan	20%	20%	22%	23%
Herceptin	107%	104%	87%	61%
Avastin	294%	162%	101%	63%
Tamiflu	124%	49%	52%	76%
NeoRecormon/Epogin	5%	6%	5%	3%
CellCept	-7%	4%	0%	10%
Pegasys	13%	11%	19%	23%
Xeloda	20%	16%	17%	22%
Lucentis	-	-	-	-
Tarceva	2566%	867%	211%	125%
Bonviva/Boniva	-	-	885%	658%
Xenical	7%	-3%	5%	-7%
Xolair	-	-	-	-
Valcyte/Cymevene	5%	19%	21%	21%
Nutropin	-4%	10%	14%	0%
Pulmozyme	10%	10%	16%	1%
Kytril	4%	-9%	-5%	-15%
Rocephin	-9%	-8%	-10%	-5%
Neutrogen	-	-	-	-
Activase/TNKase	33%	7%	31%	-6%

¹ Roche Pharmaceuticals

9. Top Pharmaceuticals Division quarterly product sales¹ in 2006 and 2007

CHF millions	Q1 2006	Q2 2006	Q3 2006	Q4 2006	Q1 2007
MabThera/Rituxan	1,146	1,202	1,177	1,314	1,309
Herceptin	861	952	1,009	1,105	1,168
Avastin	676	713	741	832	923
Tamiflu	601	360	669	997	865
NeoRecormon/Epogin	535	565	535	592	522
CellCept	454	437	466	485	476
Pegasys	350	374	350	393	400
Xeloda	238	234	239	260	267
Lucentis	-	13	192	273	263
Tarceva	172	195	211	235	243
Bonviva/Boniva	75	92	142	179	170
Xenical	181	182	160	170	163
Xolair	124	133	135	145	136
Valcyte/Cymevene	110	113	126	139	124
Nutropin	118	126	118	132	117
Pulmozyme	109	103	108	116	111
Kytril	130	124	127	117	105
Rocephin	110	106	96	104	100
Neutrogen	93	95	91	100	96
Activase/TNKase	88	90	89	95	96

¹ Roche Pharmaceuticals, Genentech and Chugai combined

10. Pharmaceuticals Division quarterly product sales¹ in US in 2006 and 2007

CHF millions	Q1 2006	Q2 2006	Q3 2006	Q4 2006	Q1 2007
MabThera/Rituxan	634	675	650	737	682
Herceptin	375	400	374	398	383
Avastin	516	527	539	606	657
Tamiflu	168	108	361	275	147
NeoRecormon/Epogin	-	-	-	-	-
CellCept	221	215	241	264	217
Pegasys	103	115	107	122	104
Xeloda	92	90	90	111	89
Lucentis	-	13	192	273	263
Tarceva	120	129	123	132	125
Bonviva/Boniva	69	78	122	144	120
Xenical	34	28	25	27	24
Xolair	124	133	135	145	136
Valcyte/Cymevene	55	59	68	77	56
Nutropin	114	123	115	127	114
Pulmozyme	64	58	62	66	65
Kytril	57	43	56	39	39
Rocephin	9	8	6	2	6
Neutrogen	-	-	-	-	-
Activase/TNKase	78	78	78	81	88

¹ Roche Pharmaceuticals and Genentech combined

11. Pharmaceuticals Division quarterly product sales¹ in Japan in 2006 and 2007

CHF millions	Q1 2006	Q2 2006	Q3 2006	Q4 2006	Q1 2007
MabThera/Rituxan	41	48	49	56	38
Herceptin	32	38	40	46	36
Avastin	-	-	-	-	-
Tamiflu	170	9	57	173	246
NeoRecormon/Epogin	160	182	147	194	124
CellCept	7	8	8	9	7
Pegasys	17	16	14	15	10
Xeloda	6	7	7	7	6
Lucentis	-	-	-	-	-
Tarceva	-	-	-	-	-
Bonviva/Boniva	-	-	-	-	-
Xenical	-	-	-	-	-
Xolair	-	-	-	-	-
Valcyte/Cymevene	-	-	-	-	-
Nutropin	-	-	-	-	-
Pulmozyme	-	-	-	-	-
Kytril	29	36	34	40	29
Rocephin	13	16	13	17	12
Neutrogen	93	95	91	100	96
Activase/TNKase	-	-	-	-	-

¹ Chugai

12. Pharmaceuticals Division quarterly product sales in Europe/Rest of World¹ in 2006 and 2007

CHF millions	Q1 2006	Q2 2006	Q3 2006	Q4 2006	Q1 2007
MabThera/Rituxan	471	479	478	521	589
Herceptin	454	514	595	661	749
Avastin	160	186	202	226	266
Tamiflu	263	243	251	549	472
NeoRecormon/Epogin	375	383	388	398	398
CellCept	226	214	217	212	252
Pegasys	230	243	229	256	286
Xeloda	140	137	142	142	172
Lucentis	-	-	-	-	-
Tarceva	52	66	88	103	118
Bonviva/Boniva	6	14	20	35	50
Xenical	147	154	135	143	139
Xolair	-	-	-	-	-
Valcyte/Cymevene	55	54	58	62	68
Nutropin	4	3	3	5	3
Pulmozyme	45	45	46	50	46
Kytril	44	45	37	38	37
Rocephin	88	82	77	85	82
Neutrogen	-	-	-	-	-
Activase/TNKase	10	12	11	14	8

¹ Roche Pharmaceuticals